Clinical Scorecard: FDA expands gastroesophageal cancer options
At a Glance
| Category | Detail |
|---|---|
| Condition | HER2-positive gastroesophageal adenocarcinoma |
| Key Mechanisms | Zanidatamab-hrii is a bispecific antibody targeting HER2. |
| Target Population | Adults with unresectable locally advanced or metastatic HER2-positive tumors. |
| Care Setting | Oncology |
Key Highlights
- Two first-line treatment options approved containing zanidatamab-hrii.
- Zanidatamab-hrii plus tislelizumab-jsgr and chemotherapy reduces disease progression risk by 35%.
- Median progression-free survival is 12.4 months with zanidatamab vs 8.1 months with trastuzumab.
- Zanidatamab-hrii regimens reduce risk of death by 28% compared to trastuzumab.
- Median overall survival is 26.4 months with zanidatamab-hrii plus tislelizumab-jsgr vs 19.2 months with trastuzumab.
- Diarrhea is the most common adverse reaction reported.
Guideline-Based Recommendations
Diagnosis
- HER2-positive tumors must be immunohistochemistry 3-positive or 2-positive and in situ hybridization-positive.
Management
- Zanidatamab-hrii can be used with tislelizumab-jsgr and chemotherapy or with chemotherapy alone.
Monitoring & Follow-up
- Monitor for diarrhea and other serious adverse reactions.
Risks
- Boxed warnings for diarrhea and embryo-fetal toxicity.
Patient & Prescribing Data
Patients with HER2-positive gastroesophageal adenocarcinoma.
Serious adverse reactions occurred in 59% of patients with the combination regimen.
Clinical Best Practices
- Consider patient HER2 status when selecting treatment.
- Monitor patients closely for adverse reactions, particularly diarrhea.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
